Stock Overview

Becton Dickinson and Company (BDX)

NYSE · Healthcare · Medical Instruments & Supplies

Becton Dickinson and Company is a Healthcare company with a market capitalization of $42.96B, a trailing P/E ratio of 27.3, and a dividend yield of 2.76%.

Market Cap
$42.96B
P/E (TTM)
27.3
Forward P/E
11.2
Price/Sales
1.9
Price/Book
1.7
EV/EBITDA
11.7
Dividend Yield
2.76%
Beta
0.28
EPS (TTM)
$5.72
Profit Margin
5.1%
ROE
6.7%
52W High
$184.86
52W Low
$125.21

5-Year Price History

Latest Annual Financials · FY ending September 30, 2025

Revenue
$21.84B
Gross Profit
$9.92B
Operating Income
$2.58B
Net Income
$1.68B
Free Cash Flow
$2.67B
Total Debt
$19.18B
Cash & Equivalents
$851.00M
Shareholder Equity
$25.39B

Recent Quarterly Earnings (EPS)

QuarterReportedActual EPSEstimateSurprise
Q2 2026May 7, 2026$2.90$2.77+4.7%
Q1 2025February 9, 2026$2.91$2.80+3.9%
Q4 2025November 6, 2025$3.96$3.91+1.3%
Q3 2025August 7, 2025$3.68$3.40+8.2%
Q2 2025May 1, 2025$3.35$3.28+2.1%
Q1 2024February 5, 2025$3.43$2.99+14.7%

Other Medical Instruments & Supplies Stocks

Frequently Asked Questions

What is Becton Dickinson and Company's market cap?

As of June 29, 2026, Becton Dickinson and Company (BDX) has a market capitalization of $42.96B.

What is Becton Dickinson and Company's P/E ratio?

Becton Dickinson and Company trades at a trailing price-to-earnings (P/E) ratio of 27.3. Its forward P/E is 11.2.

Does Becton Dickinson and Company pay a dividend?

Yes — Becton Dickinson and Company pays a dividend yielding 2.76%, an annual payout of $4.18 per share.

What sector is BDX in?

Becton Dickinson and Company is in the Healthcare sector, specifically the Medical Instruments & Supplies industry.

What was Becton Dickinson and Company's revenue?

In its latest reported fiscal year (ending September 30, 2025), Becton Dickinson and Company reported revenue of $21.84B and net income of $1.68B.

Ask your own questions about BDX

Try mrmarket.ai free

Data as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.